8IM1.F Implantica AG
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 8IM1.F undervalued?
Graham numberThe Graham number of Implantica AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Implantica AG fundamental analysis
No fundamental analysis for Implantica AG yet.
Implantica AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland and Spain. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system monitor, transmit, and actively treat conditions from within the body; e-InVivo, a sensor …
Full company profileImplantica AG financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Implantica AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|
| Cash Flow | |||||||
| Operating Cash Flow | -1.76M | -3.73M | -3.57M | -10.4M | -11.5M | -16.0M | - |
| Capital Expenditure | 96.1K | 35.8K | 8.00K | 31.0K | 164K | 61.0K | 0.00 |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Implantica AG dividends
Implantica AG has not paid dividends in the last 8 fiscal years.
Who owns Implantica AG
- Insiders 0.00%
- Institutions 12.16%
- Public & others 87.84%
- Free float 29.8M
Implantica AG company profile
- Company name
- Implantica AG
- Ticker
- 8IM1.F
- ISIN
- SE0014855029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 46
- Fiscal year end
- December
- Address
- Aeulestrasse 45, Vaduz, Liechtenstein, 9490
- Phone
- 41 41 539 19 02
- Website
- implantica.com
About Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland and Spain. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system monitor, transmit, and actively treat conditions from within the body; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.
Implantica AG management
8- Dr. Peter ForsellFounder & CEO · born 1954
- Mr. Andreas ÖhrnbergChief Financial Officer · born 1978
- Mr. Stephan SiegenthalerChief Strategy Officer & Board Member · born 1957
- Ms. Nicole PehrssonChief Corporate Affairs Officer · born 1966
- Ms. Juanita EberhartVice President of Marketing & Advocacy
- Mr. Amit KukrejaChief Market Access & Strategy Officer · born 1983
- Ms. Melanie HouselogSenior Director & Head of Global QA RA
- Mr. Jörg von Manger-KoenigCompany Secretary & Member of Advisory Board · born 1960